drugset / Trial / NCT02487316
A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
Phase 4
Withdrawn
Jun Zhu
Air Force General Hospital of the PLA · collabAnhui Provincial Hospital · collabBeijing Hospital · collabCancer Institute and Hospital, Chinese Academy of Medical Sciences · collabChinese PLA General Hospital · collabFirst Hospitals affiliated to the China PLA General Hospital · collabPeking Union Medical College Hospital · collabPeking University First Hospital · collabPeking University People's Hospital · collabPeking University Third Hospital · collabZhejiang University · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the efficacy and safety of crizotinib combined with CHOP chemotherapy for patients with ALK(+) Systemic Anaplastic Large Cell Lymphoma.
Timeline
- Start
- 2015-07
- Primary completion
- 2017-11
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crizotinib | Small molecule | 250 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Background | Prednisone | Other / unclassified | 100 mg | — |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | — |